CRISPR Screen Shows ALDH3B2 Knockout Raises Human Duct-to-Beta Cell Conversion to 8.5%

{"Researchers engineered immortalized human duct cells with a fluorescent beta-cell reporter and performed CRISPR knockout across >19,000 genes. ALDH3B2 loss triggered loss of duct identity, activation of insulin-processing genes, and demethylation of the insulin promoter. Transplanted reprogrammed cells normalized glucose in diabetic mice, demonstrating functional output beyond reporter fluorescence.","This approach targets the patient's own duct cells, bypassing donor shortages and immunosuppression required for islet or stem-cell transplants. Current diabetes care relies on exogenous insulin that cannot match physiologic secretion; an 8.5% conversion rate, while modest, represents an order-of-magnitude gain over spontaneous reprogramming and offers an autologous route to beta-cell restoration.","The study is an in-vitro screen plus mouse xenograft; it does not address in-vivo delivery, off-target CRISPR effects, or long-term stability of the reprogrammed state. Next required steps include large-animal safety studies, optimized non-viral delivery to the pancreas, and assessment of whether the 8.5% efficiency scales to clinically meaningful beta-cell mass in humans."}